NCT00781274

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.

Conditions

• Hepatitis C

Interventions

Type	Name	Description
DRUG	MP-424	750 mg every 8 hours for 12 weeks
DRUG	Ribavirin	600 - 1000 mg/day based on body weight for 24 weeks
DRUG	Peginterferon Alfa-2b	1.5 mcg/kg/week for 24 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2008-10-28
• Last updated: 2026-01-06
• Results posted: 2012-08-20

Locations

1 site across 1 country: Japan